Cargando…
Racial disparities in women with ST elevation myocardial infarction: A National Inpatient Sample review of baseline characteristics, co‐morbidities, and outcomes in women with STEMI
BACKGROUND: A third of the patients admitted with Acute coronary syndrome (ACS) have ST‐elevation myocardial infarction (STEMI). Previous studies showed that females with STEMI have higher mortality than men. HYPOTHESIS: There exist significant disparities in outcomes among women of different races...
Autores principales: | Senthil Kumaran, Sriviji, Del Cid Fratti, Juan, Desai, Anjali, Garg, Rimmy, Requeña‐Armas, Carlos, Barzallo, Pablo, Henien, Mena, Ahmad, Mansoor, Mungee, Sudhir, Mukhopadhyay, Ekanka, Kizhakekuttu, Tinoy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577545/ https://www.ncbi.nlm.nih.gov/pubmed/37443449 http://dx.doi.org/10.1002/clc.24068 |
Ejemplares similares
-
Association Between Pulmonary Hypertension and Its Effect on 30-Day Mortality, Readmission, and Cost After Transcatheter Aortic Valve Replacement: A Multicenter Study
por: Ahmad, Mansoor, et al.
Publicado: (2023) -
Left Ventricular Ejection Fraction along with Zwolle Risk Score for Risk Stratification to Enhance Safe and Early Discharge in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: A Retrospective Observational Study
por: Banga, Sandeep, et al.
Publicado: (2019) -
Management of Resistant Hypertension Based on Recommendations from Different Guidelines and the Systolic Blood Pressure Intervention Trial
por: Banga, Sandeep, et al.
Publicado: (2019) -
A Phase II Prospective, Randomized, Double‐Blind, Placebo‐Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor‐Positive Postmenopausal Women with Early Stage Breast Cancer in Treatment with Aromatase Inhibitor in the Adjuvant Setting
por: Sánchez‐Rovira, Pedro, et al.
Publicado: (2020) -
Single‐Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
por: García‐Alfonso, Pilar, et al.
Publicado: (2018)